Chemistry:Ralpancizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | neural apoptosis-regulated proteinase 1 |
| Clinical data | |
| Other names | RN317 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6422H9922N1730O2012S54 |
| Molar mass | 145289.36 g·mol−1 |
Ralpancizumab (INN;[1] development code RN317) is a monoclonal antibody designed for the treatment of dyslipidemia.[2][3]
This drug was developed by Pfizer.
References
- ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110". WHO Drug Information 27 (4). https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf.
- ↑ "Ralpancizumab". Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. http://www.ama-assn.org/resources/doc/usan/x-pub/ralpancizumab.pdf..
- ↑ "A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy". Clinical and Translational Science 10 (1): 3–11. January 2017. doi:10.1111/cts.12430. PMID 27860267.
 |  |
